Haleon PLC (HLN) FY2024Q3 Earning Prediction
Haleon PLC (HLN) is set to release its FY2024Q3 earnings performance on 10/31 ET in Pre-Market trading. Consensus forecasts predict a revenue of 2.85B and an earnings per share (EPS) of 0.11 for the FY2024Q3. With Intellectia's exclusive AI algorithms, users can predict whether the earnings will beat or miss expectations before the report drops. Leverage this powerful tool to strategize and position your trades ahead of the earnings release!
AI Earnings Prediction
The earnings forecast is neutral, reflecting potential revenue growth from Eroxon offset by challenges in the VMS sector and margin pressures.
Scenario Analysis
Key Indicators Forecast
No data
Prediction Logic & Rational
Logic & Justification
- Revenue: The launch of Eroxon, the first FDA-cleared OTC gel for erectile dysfunction, provides a near-term revenue catalyst. Its availability via Amazon pre-orders and major retailers by October could drive incremental sales. However, Morgan Stanley’s revised Q3 revenue growth forecast (to +
6.3% from +
7.5%) highlights challenges in vitamins/minerals/supplements (VMS) in the U.S., offsetting some upside.
2. EPS: EPS revisions (-46% over 3 months) signal margin pressures. While Eroxon’s margins could be favorable, Morgan Stanley’s focus on "challenging comps" and potential cost inefficiencies in VMS likely weigh on profitability.
- Market Sentiment: Mixed analyst actions (price target cuts but maintained Buy ratings) suggest cautious optimism. The Pfizer share offering (640M shares) introduces dilution risk but does not directly impact operational performance.
Tactical Strategy Recommendations
Trading Strategy
- Options Straddle: Buy both calls and puts (e.g., $10 strike) to capitalize on volatility from Eroxon’s uncertain impact and margin risks.
- Cautious Long: Consider shares with a tight stop-loss (~$9.50) to hedge against dilution/Pfizer selling pressure.
- Earnings Pair Trade: Short Haleon vs. long peers with clearer margin visibility (e.g., consumer health stocks less exposed to VMS).
Rationale: Uncertainty around Eroxon’s launch timing and margin trajectory justifies a neutral stance, but asymmetric risks (downside EPS vs. upside revenue) favor hedging.
Earnings Surprise Analysis
HLN Transcript
The earnings call summary presents a mixed picture: strong growth in Oral Health and market share gains in some areas are offset by challenges in the U.S. market and specific product lines like Advil and Centrum. The Q&A reveals management's cautious optimism, but also highlights issues like inventory pressures and competitive losses. Despite some positive elements, such as innovation and investment in key markets, the overall sentiment remains balanced due to unresolved challenges and uncertainties, leading to a neutral outlook for the stock price over the next two weeks.
The earnings call presents a mixed picture: positive revenue growth in key areas like Oral Health and a strong performance in India, but challenges in VMS and Centrum sales, along with foreign exchange headwinds. The lack of a share buyback or dividend program and unclear management responses contribute to uncertainty. The Q&A reveals cautious optimism for the second half, but no strong catalysts are present to suggest a significant stock price movement. Without a market cap, the stock's reaction is uncertain but likely neutral in the short term.
The earnings call reveals mixed signals: strong organic growth in key areas like Oral Health, but overall revenue is affected by foreign exchange headwinds and disposals. The company maintains stable margins and financial health, but lacks a share buyback program. The Q&A section highlights management's confidence in future growth through innovation and investment, but also notes consumer softness and tariff challenges. The absence of a new partnership or significant shareholder returns tempers positive sentiment. Without a market cap, the stock's reaction is uncertain, thus a 'Neutral' rating is appropriate.
HLN Report
Frequently Asked Questions
What is the Haleon PLC FY2024Q3 Earnings Release Date and Time?
Haleon PLC (HLN) is scheduled to release its FY2024Q3 earnings report onOct 31, 2024, Pre-Market(approximately 4:00 PM ET). This timing allows investors to react during after-hours trading, with a conference call typically following shortly after.
What Are the Consensus Forecasts for Haleon PLC FY2024Q3 Revenue and EPS?
Analysts' consensus predicts 2.85B in revenue and an EPS of 0.11 for Haleon PLC's FY2024Q3.
What Does Intellectia's AI Predict for Haleon PLC FY2024Q3 Earnings?
Intellectia's exclusive AI algorithms forecast a Neutral forHaleon PLC's FY2024Q3 earnings, with a prediction date of Oct 31, 2024. Haleon PLC The earnings forecast is neutral, reflecting potential revenue growth from Eroxon offset by challenges in the VMS sector and margin pressures.
How Can I Use This Earnings Prediction to Trade HLN Stock?
Leverage Intellectia's AI forecast to position trades ahead of theOct 31, 2024 release—consider calls for a beat scenario or protective puts for misses. Focus on pre-market volatility, and use the scenario probabilities to build strategies around revenue and guidance updates.
How Accurate Is Intellectia's AI for Earnings Predictions Like Haleon PLC FY2024Q3?
Intellectia's predictions are backed by rigorous backtesting, showing a high hit rate for Beat and Miss calls compared to traditional analysis. While no forecast is 100% certain, we provide probability-based scenarios (e.g., 50% chance of a *Beat*) and detailed rationales to help you make informed decisions. Combine our insights with your strategy for the best results—it's like having a co-pilot for earnings season! Empowering users to strategize trades before reports drop.
How does AI Earnings Prediction generate its forecasts?
AI Earnings Prediction uses advanced Large Language Models (LLMs) to analyze a wealth of data, including past earnings transcripts, real-time market sentiment, analyst insights, and company news from the last three months. It focuses on key indicators like revenue, EPS, and margins to predict whether a company will *Beat*, *Miss*, or remain Neutral relative to market expectations. Think of it as a super-smart analyst crunching numbers and news 24/7 to give you a trading edge!
When are the predictions available, and how often are they updated?
Predictions are generated two days before a company’s earnings release (e.g., 5:00 PM ET on Feb 13 for a Feb 15 report) to capture the latest market and company data. They’re updated in real-time if significant news breaks, ensuring you get fresh insights.
Can I use AI Earnings Prediction for all types of stocks?
Currently, AI Earnings Prediction focuses on companies with market caps above $40 billion, covering major players like SPG, AAPL, MSFT, and NVDA for the 2025-2026 earnings seasons. We prioritize high-impact stocks with robust data to ensure reliable forecasts. Stay tuned as we expand coverage to more companies based on user demand!
